Statement of Stockholders' Equity (Deficit) (USD $)	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Deficit During the Development Stage [Member]
Balance at Jul. 31, 2005
Balance, shares at Jul. 31, 2005
Common shares issued for cash during March 2006 at $0.001 per share	5,000	5,000
Common shares issued for cash during March 2006 at $0.001 per share, shares		5,000,000
Common shares issued for cash during March 2006 at $0.01 per share	13,000	1,300	11,700
Common shares issued for cash during March 2006 at $0.01 per share, shares		1,300,000
Common shares issued for cash during April 2006 at $0.01 per share	7,500	75	7,425
Common shares issued for cash during April 2006 at $0.01 per share, shares		75,000
Common shares issued for cash during May 2006 at $0.01 per share	30,000	150	29,850
Common shares issued for cash during May 2006 at $0.01 per share, shares		150,000
Net income (loss)	(32,125)			(32,125)
Balance at Jul. 31, 2006	23,375	6,525	48,975	(32,125)
Balance, shares at Jul. 31, 2006		6,525,000
Net income (loss)	(33,605)			(33,605)
Balance at Jul. 31, 2007	(10,230)	6,525	48,975	(65,730)
Balance, shares at Jul. 31, 2007		6,525,000
Net income (loss)	(17,924)			(17,924)
Balance at Jul. 31, 2008	(28,154)	6,525	48,975	(83,654)
Balance, shares at Jul. 31, 2008		6,525,000
Net income (loss)	28,444			28,444
Balance at Jul. 31, 2009	290	6,525	48,975	(55,210)
Balance, shares at Jul. 31, 2009		6,525,000
Forward Stock Split : 20 for 1		130,500	(130,500)
Forward Stock Split : 20 for 1, shares		130,500,000
Stock issued for acquisition of patent	20,333	20,333
Stock issued for acquisition of patent, shares		20,333,333
Cancellation of shares		(100,000)	100,000
Cancellation of shares, shares		(100,000,000)
Stock issued for services	1,358,800	4,150	1,354,650
Stock issued for services, shares		4,150,000
Net income (loss)	(2,016,710)			(2,016,710)
Balance at Jul. 31, 2010	(637,287)	61,508	1,373,125	(2,071,920)
Balance, shares at Jul. 31, 2010		61,508,333
Warrants issued for acquisition of patent	7,117		7,117
Sales of common stock	3,078,020	5,640	3,072,380
Sales of common stock, shares		5,640,000
Stock issued for services	6,118,170	9,828	6,108,342
Stock issued for services, shares		9,828,000
Stock based compensation from issuance of stock options	531,250		531,250
Net income (loss)	(9,435,787)			(9,435,787)
Balance at Jul. 31, 2011	(338,517)	76,976	11,092,214	(11,507,707)
Balance, shares at Jul. 31, 2011		76,976,333
Cancellation of shares		(220)	220
Cancellation of shares, shares		(220,000)
Sales of common stock	802,929	8,439	794,490
Sales of common stock, shares		8,438,572
Stock issued for services	10,048,857	37,556	10,011,301
Stock issued for services, shares		37,555,668
Conversion of Convertible Notes Payable to Common Stock	100,000	3,332	96,668
Conversion of Convertible Notes Payable to Common Stock, shares		3,332,843
Stock based compensation from issuance of stock options	1,027,501		1,027,501
Stock based compensation from issuance of stock warrants	161,700		161,700
Net income (loss)	(12,421,188)			(12,421,188)
Balance at Jul. 31, 2012	(618,718)	126,083	23,184,094	(23,928,895)
Balance, shares at Jul. 31, 2012	126,083,416	126,083,416
Sales of common stock	55,000	917	54,083
Sales of common stock, shares		916,667
Stock issued for services	802,074	8,295	793,779
Stock issued for services, shares		8,295,264
Conversion of Convertible Notes Payable to Common Stock	544,087	10,410	533,677
Conversion of Convertible Notes Payable to Common Stock, shares		10,410,182
Stock based compensation from issuance of stock options	711,833		711,833
Stock based compensation from issuance of stock warrants	152,450		152,450
Investment in Overdose Progam	600,000		600,000
Net income (loss)	(2,786,358)			(2,786,358)
Issuance of Common Stock as Deferred Financing Cost	13,500	100	13,400
Issuance of Common Stock as Deferred Financing Cost, shares		100,000
Balance at Apr. 30, 2013	$ (526,132)	$ 145,805	$ 26,043,316	$ (26,715,253)
Balance, shares at Apr. 30, 2013	145,805,529	145,805,529